



Preoperative Three-Dimensional Lung Simulation Before Thoracoscopic Anatomical Segmentectomy for Lung Cancer: A Systematic Review and Meta-Analysis

Zhongtian Xiang, Bo Wu, Xiang Zhang, Nan Feng, Yiping Wei, Jianjun Xu and Wenxiong Zhang *

Department of Thoracic Surgery, The Second Affiliated Hospital of Nanchang University, Nanchang, China

Background: Whether the utilization of preoperative three-dimensional (3D) lung simulation can improve the outcomes of segmentectomy for lung cancer (LC) is still controversial. Our meta-analysis was performed to compare preoperative 3D lung simulation with non-3D procedures in terms of perioperative outcomes.

OPEN ACCESS

Edited by:

Alexander Kluge, Institute of Diagnostic and Interventional Radiology, Germany

Reviewed by:

Jean-marc Baste, Centre Hospitalier Universitaire (CHU) de Rouen, France Patrick Zardo, Hannover Medical School, Germany

> *Correspondence: Wenxiong Zhang zwx123dr@126. com

Specialty section:

This article was submitted to Thoracic Surgery, a section of the journal Frontiers in Surgery

Received: 17 January 2022 Accepted: 10 March 2022 Published: 31 March 2022

Citation:

Xiang Z, Wu B, Zhang X, Feng N, Wei Y, Xu J and Zhang W (2022) Preoperative Three-Dimensional Lung Simulation Before Thoracoscopic Anatomical Segmentectomy for Lung Cancer: A Systematic Review and Meta-Analysis. Front. Surg. 9:856293. doi: 10.3389/fsurg.2022.856293 **Methods:** Seven databases (Embase, Ovid Medline, ScienceDirect, PubMed, Web of Science, Cochrane Library, and Scopus) were searched for eligible articles. Intraoperative outcomes (conversion, operative time, etc.), postoperative indicators (postoperative hospital stay, total number of complications, etc.) and postoperative complications were endpoints.

Results: After applying predefined inclusion criteria, we included 8 studies and 989 patients (3D group: 552 patients; non-3D group: 437 patients) in our meta-analysis. The results of the meta-analysis showed that preoperative 3D lung simulation could significantly decrease the blood loss (mean difference [MD]: -16.21 [-24.95 to -7.47]ml, p = 0.0003), operative time (MD: -13.03 [-25.56 to -0.50]ml, p = 0.04), conversion rate (conversion from segmentectomy to thoracotomy or lobectomy) (MD: 0.12 [0.03-0.48], p = 0.003), postoperative hospital stay (MD: -0.25 [-0.46 to 0.04]days, p = 0.02) and total number of complications (MD: 0.59 [0.43-0.82], p = 0.001) compared with non-3D procedures. The number of resected lymph nodes (LNs), postoperative drainage time, postoperative forced expiratory volume in the first second (postoperative FEV1) and postoperative drainage volume were similar in the two groups. Arrhythmia (5.30%), pulmonary air leakage (2.72%), atrial fibrillation (2.20%), pulmonary infection (2.04%), and pneumonia (1.73%) were the top 5 postoperative complications in the 3D group.

Conclusions: Preoperative 3D lung simulation was better than non-3D procedures in segmentectomy for LC, with better intraoperative and postoperative outcomes. However, our results should be confirmed in larger prospective randomized controlled trials.

Systematic Review Registration: PROSPERO, identifier: CRD42021275020.

Keywords: segmentectomy, lung cancer, systematic review, meta-analysis, three-dimensional lung simulation

INTRODUCTION

Lung cancer (LC) remains the leading cause of cancer death, and it is the cancer with the highest incidence (1). In recent years, the detection rate of early non-small-cell lung cancer (NSCLC) has increased significantly with the introduction of thin-section and low-dose computed tomography (2). The application of segmentectomy, which is associated with less trauma, fewer complications, and less pain for patients than thin-section and low-dose computed tomography, is more conducive for patients with non-small-cell lung cancer (3). 3D computed tomography of lung segments can ensure the position of the lung tumor within the anatomical segment and assist in the prediction of surgical margins (4). However, whether preoperative 3D lung simulation is better than non-3D procedures in segmentectomy for lung cancer remains controversial.

Whether preoperative 3D lung simulation is better than non-3D procedures in segmentectomy for LC has not yet been confirmed by guidelines (5). Liu et al., Chen et al., and Xu et al. suggested that preoperative 3D simulations for the assessment of pulmonary vessel and bronchi branching patterns could improve surgical accuracy and safety (6–8). Similarly, Hu et al., Xue et al., She et al., and Qiu et al. all reported that preoperative 3D lung simulation shortened the operation time and reduced intraoperative blood loss and intraoperative and postoperative complications, especially in patients with stage IA NSCLC (9–12). However, Wu et al. suggested that conventional segmentectomy can obviously reduce the time of operation and can protect the lung from air leakage, although a sufficient resection margin and lymph node dissection might be ensured by preoperative 3D lung simulation (13).

To verify the reliability and safety of this method, we compared the intraoperative and postoperative indicators of the included patients for whom preoperative 3D lung simulation was performed with those of patients for whom it was not performed.

MATERIALS AND METHODS

This meta-analysis followed the guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) (**Supplementary Table 1**) (14). (PROSPERO Registration: CRD42021275020).

Search Strategy

Seven databases (Embase, Cochrane Library, Scopus, PubMed, Ovid Medline, Web of Science, and Science Direct) were searched from their inception date to the 26th of August 2021. We used the MeSH terms "three-dimensional" and "segmentectomy" as follows. The gray literature, abstracts and bibliographies were investigated for additional qualified reports. The comprehensive retrieval scheme is shown in **Supplementary Table 2**.

Selection Criteria

Inclusion criteria:

- (1) Sample: patients with lung cancer who underwent segmentectomy.
- (2) Intervention and comparison: preoperative 3D lung simulation compared with non-3D procedures.
- (3) Outcomes: intraoperative outcomes (blood loss, operative time, conversion, number of resected LNs) and hospitalization and follow-up outcomes (postoperative drainage time, total number of complications, postoperative drainage volume, postoperative FEV1 and postoperative hospital stay).
- (4) Study design: RCTs and cohort studies.

Only studies of human subjects were included. If the institution published repeated trials and patient cohorts were included, we selected the most recent complete study for evaluation. Commentaries, expert recommendations, editorials, and conference abstracts were excluded. Because of the possibility of the duplication of results or publication bias, we also excluded review articles.

Data Extraction

We constructed a standardized data extraction table in which to record the following data from the included studies: publication year, first author, nation, study period, patient characteristics (sex, age), tumor characteristics (location, histology), intraoperative outcomes (blood loss, operative time, conversion, number of resected LNs), and postoperative outcomes (postoperative drainage time, total number of complications, postoperative drainage volume, postoperative FEV1 and postoperative hospital stay). When a study had both propensity-matched and non-propensity-matched data, we chose the propensity-matched data for the included analysis. The extraction of data from all included studies was performed independently by 2 investigators. In the case of disagreement, a third coauthor's opinion was sought, and the disagreement was resolved by consensus.

Quality Assessment

We utilized the Newcastle–Ottawa Scale (NOS) to evaluate the quality of 8 searched studies. This scale contained 3 items: comparability, outcome, and selection. Each study was scored based on the above three factors on a scale of 0–9 (allocated as stars), and studies with scores \geq 7 were defined as being of high quality, those with scores \leq 4 points low quality, and those with scores \geq 5 but \leq 6 points medium quality (15). The 5-point Jadad scale was applied to evaluate the quality of RCTs. Three items were included in the scale: the masking, randomization, and accountability of included patients. Scores \geq 3 points indicated high quality (16).

A Grades of Recommendations Assessment, Development and Evaluation (GRADE) table was applied to assess the evidence level of those results. This standard included 5 items: indirectness, risk of bias, publication bias, indirectness

Abbreviations: 3D, Three-dimensional; CI, confidence interval; FEV1, Forced Expiratory Volume in the first second; GRADE, Grading of Recommendations Assessment, Development and Evaluation; HR, hazard ratio; LC, Lung cancer; LNs, lymph nodes; MD, mean difference; NOS, Newcastle-Ottawa Scale; NSCLC, Non-small cell lung cancer; OP, operation; PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses; RCT, randomized clinical trial; RR, risk ratio; SMD, standardized mean difference; TNM, Tumor Node Metastasis.

imprecision and inconsistency. Studies were evaluated as having a high, moderate, low or very low level of evidence (17).

The Analysis of Statistical Data

We performed statistical analysis using STATA 12.0 and Review Manager Version 5.3 (Software Update, Cochrane Collaboration, UK, Oxford). Additionally, researchers calculated the corresponding 95% confidence interval (95% CI) and computed the risk ratio (RR) for dichotomous outcomes. For continuous outcomes, the mean difference (MD) is presented. The standardized mean difference (SMD) is presented if various tables were required to measure similar basic constructions. The corresponding 95% CIs were determined for all outcomes. To evaluate heterogeneity, we mainly used the I^2 statistic and χ^2 test. We also used a random-effects model for notable heterogeneity ($I^2 > 50\%$ or p < 0.1). Otherwise, a relatively fixed-effects model was chosen. Egger's (18) and Begg's (19) tests were applied for the assessment of publication bias. In particular, differences with *P*-values <0.05 were defined as significant.

RESULTS

Search Results and the Quality of the Included Studies

Ultimately, 8 articles involving 989 patients (3D group: 552, non-3D group: 437) were included for assessment (6–13) (**Figure 1**). The baseline characteristics are shown in **Table 1**. As determined by the NOS and Jadad scale, all studies were of medium-high quality (**Table 2**). The quality evidence of the outcomes was low and very low, in line with the GRADE list (**Supplementary Table 3**).

Intraoperative Outcomes

No significant difference was reported between the two groups in the number of resected LNs (MD: 0.94 [-1.22 to 3.09], p = 0.39, Figure 2D).

The 3D group had less blood loss (mean difference [MD]: -16.21 [-24.95 to -7.47] ml, p = 0.0003, **Figure 2A**), a shorter operative time (MD: -13.03 [-25.56 to -0.50] ml, p = 0.04, **Figure 2B**) and a lower conversion rate (conversion from



TABLE 1 | Summary of the baseline characteristics of the included studies.

| Study | Nation | Period (year) | riod Groups ear) | Patients \$ | Sex (M/F) | Age (Mean, year) | | L | esion loca. | ation (lobe | s) | | Histology(ı | n) | | | | | Follow up (months |
|---------------------------|-------------------------------|------------------|---------------------|--------------------|-----------|------------------------|-------|--------|-------------|-------------|-------|----|-------------------------------------|------------------------------------|---|---------------------------------|---------------------------------|--------|-------------------------|
| | | | | | | | | Right | | | Left | | Atypical adenomate hyperplasi | Adenocarcinoma ous in situ a | Minimally invasive adenocarcinoma | Invasive adenocarcinoma I | Microinvasive adenocarcinoma | Others | |
| | | | | | | | Upper | Middle | Lower | Upper | Lower | | | | | | | | |
| 2021 | Wu et al. (13) | China | 2020.1– 2020.9 | 3D | 55 | 20/35 | 52.9 | 12 | - | 14 | 16 | 13 | - | 10 | - | 4 | 41 | _ | - |
| | | | | Non-3D | 55 | 23/32 | 53.1 | 13 | - | 13 | 16 | 13 | - | 3 | - | 6 | 46 | - | |
| 2021 | Hu et al. (9) ^a | China | 2019.1– 2020.8 | ЗD | 30 | 14/16 | 61.3 | 10 | - | 3 | 14 | 3 | 1 | 3 | 23 | 4 | - | 5 | - |
| | | | | Non-3D | 35 | 16/19 | 62.7 | 11 | - | 4 | 20 | | 5 | 2 | 5 | 22 | 5 | - | 6 |
| 2020 Chen et a (7) RCT | Chen et al. (7) RCT | China | 2016.3– 2018.9 | ЗD | 51 | 21/30 | 60.7 | 16 | - | 17 | 11 | 7 | - | - | - | - | - | - | - |
| | | | | Non-3D | 38 | 14/24 | 61.6 | 11 | - | 14 | 8 | | 5 | - | - | - | - | - | _ |
| 2020 Qiu et (12) | Qiu et al. (12) | China | 2017.4– 2019.5 | 3D-model | 31 | 6/25 | 54.5 | | 16 | | 15 | | 2 | 12 | - | 19 | 16 | - | 3.0 |
| | | | | 3D-RS ^a | 131 | 42/89 | 54.4 | | 54 | | | 77 | | 4 | 35 | - | 87 | 48 | - |
| | | | | Non-3D | 136 | 41/42 | 54.4 | | 57 | | | 79 | | 5 | 23 | - | 89 | 44 | - |
| 2019 Liu et al. (6) | Liu et al. (6) | China | 2017.10- 2018.8 | 3D-CT | 39 | 13/26 | 60.6 | 12 | - | 11 | 10 | | 6 | | | 34 | | 5 | - |
| | | | | 3D- printing | 32 | 13/19 | 61.4 | 14 | - | 4 | 11 | | 3 | | | 27 | | | 5 |
| | | | | Non-3D | 53 | 19/34 | 62.1 | 18 | - | 11 | 13 | | 11 | | | 45 | | | 8 |
| 2019 | Xu et al. (8) | China | 2017.7– 2018.11 | ЗD | 96 | 37/59 | 50.4 | 38 | - | 13 | 26 | 19 | - | - | - | 22 | 69 | - | - |
| | | | | Non-3D | 37 | 16/21 | 53.3 | 18 | - | 1 | 12 | 6 | - | - | - | 9 | 26 | - | |
| 2018 | Xue et al. (10) | China | 2016.5– 2017.2 | ЗD | 36 | 9/27 | 53.0 | 12 | - | 6 | 13 | 5 | - | 5 | - | 8 | 23 | - | 17.5 |
| | | | | Non-3D | 32 | 12/20 | 51.6 | 10 | - | 5 | 12 | 5 | - | 5 | - | 9 | 18 | - | |
| 2018 | She et al. (11) | China | 2014.1– 2017.5 | 3D | 51 | 21/30 | 59.3 | 13 | - | 15 | 13 | 10 | 5 | 23 | 17 | - | - | 6 | 12.0 |
| | | | | Non-3D | 51 | 24/27 | 58.5 | 12 | - | 14 | 13 | 13 | 3 | 20 | 19 | - | - | 9 | |

4

Frontiers in Surgery | www.frontiersin.org

3D, Three-dimensional; 3D-RS, 3D-reconstruction; M/F, male/female.

^a The number of patients in Histology (n) were inconsistent with the number of patients in Groups because some patients may have multiple lesions.

| | Study | RandomizationMasking | Accountability of all patients | | Selection | | | Comparability | σ | Outcome | | Total score |
|--|------------------------------------|---------------------------------------|--------------------------------|------------------------------------|------------------------------|-------------------------------------|---|--------------------------|-------------------------------------|--------------------------|---|----------------|
| | | | Exposed cohort ^a | Non-exposed cohort ^b | Ascertainment of exposure | Outcome of interest ^c | | Assessment of outcome | Length of follow-up ^e | Adequacy of follow-up | | |
| 2021 | Wu et al. (13) | | | * | * | * | * | ** | * | | | 7 |
| 2021 | Hu et al. (9) | | | * | * | * | | ** | * | | | 9 |
| 2020 | Chen et al. (7 RCT | ** ** (/ | * | | | | | | | | | ŝ |
| 2020 | Qiu et al. (12) | | | * | | * | * | ** | * | * | * | 00 |
| 2019 | Liu et al. (6) | | | * | | * | * | ** | * | | | 9 |
| 2019 | Xu et al. (8) | | | × | * | * | * | ** | * | | | 7 |
| 2018 | Xue et al. (10 | () | | * | * | * | * | ** | * | * | * | 6 |
| 2018 | She et al. (11 | (| | * | * | * | * | ** | * | * | * | Ø |
| ^a Repre ^b Selecti | sentativeness of ion of the non-ex | the exposed cohort; coosed cohort: | | | | | | | | | | |
| ^c Demoi | nstration that out | come of interest was not preser | nt at start of study; | | | | | | | | | |

segmentectomy to thoracotomy or lobectomy) (mean difference: 0.12 [0.03–0.48], p = 0.003, **Figure 2C**) than the non-3D group.

Hospitalization and Postoperative Indicators

The 3D group had a shorter postoperative hospital stay (MD: -0.25 [-0.46 to -0.04] days, p = 0.02, **Figure 3A**) and a lower total number of complications (MD: 0.59 [0.43–0.82], p = 0.001, **Figure 3B**) than the non-3D group. The postoperative drainage time (MD: -0.30 [0.76-0.17], p = 0.21, **Figure 3C**), postoperative drainage volume (MD: -22.00 [-190.18-146.19], p = 0.80, **Figure 3D**) and postoperative FEV1 (MD: 0.11 [-0.12 to 0.34], p = 0.36, **Figure 3E**) were similar between these two groups.

Complications

The total number of complications was similar between the two groups. In the 3D group, the top 5 complications were arrhythmia (5.30%), pulmonary air leakage (2.72%), atrial fibrillation (2.20%), pulmonary infection (2.04%) and pneumonia (1.73%). In the non-3D group, the top 5 complications were arrhythmia (8.87%), hemoptysis (8.25%), pulmonary air leakage (5.49%), pulmonary infection (2.67%), and atelectasis (2.26%) (**Table 3**).

Sensitivity Analysis

In the analysis of blood loss (**Supplementary Figure 1A**), postoperative drainage time (**Supplementary Figure 1B**) and postoperative hospital day (**Supplementary Figure 1C**), we found significant heterogeneity. The results of the sensitivity analysis suggested that the omission of each study had little influence on the reliability of the results.

Publication Bias

We analyzed the postoperative drainage time (**Supplementary** Figure 2A), operative time (**Supplementary** Figure 2B) and postoperative hospital day (**Supplementary** Figure 2C), and no evidence of publication bias was identified.

DISCUSSION

Currently, the leading cause of cancer-related mortality worldwide is still lung cancer (20). According to global epidemiological data, over 2 million individuals were affected by lung cancer in 2018 (21). At present, segmentectomy in combination with mediastinal lymph node (LN) dissection or sampling is still one of the main treatment options for patients with stage I non-small-cell lung cancer (NSCLC) (22-24). 3D imaging provides a stereoscopic view, and the visual information obtained through binocular visualization allows precise 3D preoperative planification (25). However, large-sample studies demonstrating the safety and efficacy of 3D system use are still lacking. This study is the first meta-analysis of preoperative 3D lung simulation compared with non-3D procedures during segmentectomy for lung cancer. Our results revealed that the 3D group had notably less blood loss, a shorter operative time, a lower conversion rate, a shorter postoperative hospital stay and a lower total number of complications than

TABLE 2 | Methodological quality assessments of the included studies

¹Comparability of cohorts on the basis of the design or analysis;

follow-up long enough for outcomes to occui

e Was I

| | 30 |) group | | Non- | 3D gro | up | | Mean Difference | Mean Difference |
|---|---|---|---|---|--|--|--|--|---|
| Study or Subgroup | Mean | SD | Total | Mean | SD | Total | Weight | IV, Random, 95% CI | IV. Random, 95% Cl |
| Wu 2021 | 33 | 7.5 | 55 | 28 | 9 | 55 | 14.1% | 5.00 [1.90, 8.10] | - |
| Hu 2021 | 81.3 | 42.2 | 30 | 114.3 | 50.6 | 35 | 7.3% | -33.00 [-55.56, -10.44] | |
| Chen 2020 | 43.25 | 13.63 | 51 | 96.68 | 32.82 | 38 | 11.7% | -53.43 [-64.52, -42.34] | |
| Qiu 2020 | 12.9 | 7.8 | 31 | 18.2 | 12.2 | 136 | 14.0% | -5.30 [-8.73, -1.87] | - |
| Qiu 2020* | 20.9 | 12.2 | 131 | 18.2 | 12.2 | 136 | 14.1% | 2.70 [-0.23, 5.63] | - |
| Liu 2019 | 75.1 | 57.4 | 39 | 106.3 | 70.8 | 53 | 6.3% | -31.20 [-57.43, -4.97] | |
| Liu 2019* | 69.3 | 59.9 | 32 | 106.3 | 70.8 | 53 | 5.8% | -37.00 [-65.18, -8.82] | |
| Xu 2019 | 44.3 | 18.2 | 96 | 42.2 | 14 | 37 | 13.5% | 2.10 [-3.70, 7.90] | |
| Xue 2018 | 106.4 | 59.2 | 36 | 129.1 | 79.2 | 32 | 4.6% | -22,70 [-56,27, 10,87] | |
| She 2018 | 96.4 | 47.5 | 51 | 131.7 | 48.5 | 51 | 8.7% | -35.30 [-53.93, -16.67] | |
| Total (95% CI) | | | 552 | | | 626 | 100.0% | -16 21 [-24 95 -7 47] | • |
| Hotorogonoity: Tou ² - | 120 61. | Chi2 - 1 | 47.20 | df = 0 /5 | | 0011.1 | 2 - 040/ | | |
| Test for everall effect | 7 - 2 64 | | 0002 | ui – 9 (r | - < 0.00 | 001), I | - 94 70 | | -50 -25 0 25 50 |
| rest for overall effect. | 2 - 3.04 | (P = 0. | 0003) | | | | | | Favours [3D group] Favours [Non-3D group] |
| | 30 | aroun | | Non | 3D are | | | Maan Difference | Mean Difference |
| Study or Subaroup | Mean | sioup Sn | Total | Mean | SD gro | Total | Weight | IV Random 95% Cl | IV Random 95% Cl |
| | 74 | 14.0 | <u> </u> | EF | 17.0 | | 10 70/ | 10 00 [12 02 05 00] | |
| | 106 5 | 14.0 | 25 | 144 4 | 17.8 | 35 | 10.7% | 14.00 [24.70, 4.00] | |
| Tu 2021 | 120.5 | 35.4 | 30 | 141.4 | 33.7 | 35 | 9.2% | - 14.90 [-31.79, 1.99] | |
| Chen 2020 | 124.2 | 14.4 | 51 | 153 | 24.6 | 38 | 10.5% | -20.80 [-37.36, -20.04] | |
| QIU 2020 | 98.94 | 20.99 | 31 | 117.51 | 29.55 | 136 | 10.4% | -18.57 [-27.47, -9.67] | |
| Qiu 2020* | 112.41 | 34.53 | 131 | 117.51 | 29.55 | 136 | 10.6% | -5.10 [-12.82, 2.62] | |
| Liu 2019 | 115.5 | 37.2 | 39 | 133 | 35.7 | 53 | 9.5% | -17.50 [-32.62, -2.38] | |
| Liu 2019* | 111.1 | 36.2 | 32 | 133 | 35.7 | 53 | 9.4% | -21.90 [-37.70, -6.10] | |
| Xu 2019 | 173.5 | 35.1 | 96 | 168.8 | 52.2 | 37 | 8.9% | 4.70 [-13.53, 22.93] | |
| Xue 2018 | 111 | 1275 | 36 | 130 | 12 75 | | 10.7% | -28 001-34 07 -21 031 | - |
| | | 12.70 | | 100 | 12.70 | 52 | 10.170 | -20.00 [-04.07, -21.00] | |
| She 2018 | 141.9 | 29.1 | 51 | 160.9 | 31.5 | 51 | 10.0% | -19.00 [-30.77, -7.23] | |
| She 2018 Total (95% CI) | 141.9 | 29.1 | 51 552 | 160.9 | 31.5 | 51 626 | 10.0% | -19.00 [-34.07, -7.23] -13.03 [-25.56, -0.50] | |
| She 2018 Total (95% CI) Heterogeneity: Tau ² = 3 | 141.9 370.60: 0 | 29.1 | 51 552 51.73. 0 | 160.9 df = 9 (P | 31.5 | 51 626 001): 1 ² | 10.0% 100.0% = 94% | -13.03 [-25.56, -0.50] | |
| She 2018 Total (95% CI) Heterogeneity: Tau ² = 3 Test for overall effect: 2 | 141.9 370.60; 0 Z = 2.04 | 29.1 Chi ² = 18 (P = 0.0 | 51 552 51.73, 0 (4) | 160.9 df = 9 (P | 31.5 | 51 626 001); I ² | 10.0% 100.0% = 94% | -19.00 [-01.07, -7.23] -13.03 [-25.56, -0.50] | -50 -25 0 25 50 Favours [3D group] Favours [Non-3D group] |
| She 2018 Total (95% CI) Heterogeneity: Tau ² = 3 Test for overall effect: 2 | 141.9 370.60; (Z = 2.04 30 | 29.1 Chi ² = 1 (P = 0.0 | 51 552 51.73, 0 (4) | 160.9 df = 9 (P | 31.5 < 0.000 | 51 626 001); I ² | 10.0% 100.0% = 94% | -19.00 [-00.77, -7.23] -13.03 [-25.56, -0.50] | -50 -25 0 25 50 Favours [3D group] Favours [Non-3D group] |
| She 2018 Total (95% CI) Heterogeneity: Tau ² = 3 Test for overall effect: 2 Study or Subgroup | 141.9 370.60; 0 Z = 2.04 3E | 29.1 Chi ² = 18 (P = 0.0) group | 51 552 51.73, 0 (4) | 160.9 df = 9 (P Non-3D | 31.5 < 0.000 group | 51 626 001); I ² | 10.0% 100.0% = 94% | -19.00 [-00.77, -7.23] -13.03 [-25.56, -0.50] -13.03 [-25.56, -0.50] - | -50 -25 0 25 50 Favours [3D group] Favours [Non-3D group] Risk Ratio |
| She 2018 Total (95% CI) Heterogeneity: Tau ² = 3 Test for overall effect: 2 Study or Subgroup | 141.9 370.60; (Z = 2.04 3E 5 Eve | 29.1 Chi ² = 1 (P = 0.0) group ents T | 51 552 51.73, 0 (4) otal | 160.9 df = 9 (P Non-3D Events | 31.5 < 0.000 group Tot | 51 626 001); I ² | 10.0% 100.0% = 94% | -19.00 [-01.07, -7.23] -13.03 [-25.56, -0.50] Risk Ratio | -50 -25 0 25 50 Favours [3D group] Favours [Non-3D group] Risk Ratio M-H. Fixed, 95% Cl |
| She 2018 Total (95% CI) Heterogeneity: Tau ² = 3 Test for overall effect: 2 Study or Subgroup Chen 2020 | 141.9 370.60; (Z = 2.04 3E 5 Eve | 29.1 Chi ² = 15 (P = 0.0) group ents T 0 | 51 552 51.73, o (4) 0 0 51 | 160.9 df = 9 (P Non-3D Events 8 | 31.5 < 0.000 group Tot | 51 626 001); I ² a <u>l We</u> 38 5 | 10.0% 100.0% = 94% <u>eight N</u> 3.6% | -19.00 [-01.07, -7.23] -13.03 [-25.56, -0.50] -13.03 | -50 -25 0 25 50 Favours [3D group] Favours [Non-3D group] Risk Ratio M-H, Fixed, 95% Cl |
| She 2018 Total (95% CI) Heterogeneity: Tau ² = 3 Test for overall effect: 2 Study or Subgroup Chen 2020 Liu 2019 | 141.9 370.60; 0 Z = 2.04 3D Eve | 29.1 Chi ² = 19 (P = 0.0) group ents T 0 1 | 51 552 51.73, 0 (4) 51 51 39 | 160.9 df = 9 (P Non-3D Events 8 5 | 31.5 < 0.000 group Tot | 51 626 001); I ² al We 38 5 53 2 | 10.0% 100.0% = 94% <u>aight N</u> 3.6% 3.4% | -19.00 [-0.07, -7.23] -13.03 [-25.56, -0.50] -13.03 [-25.56, -0.50] - Risk Ratio <u>A-H. Fixed, 95% Cl</u> 0.04 [0.00, 0.74] 0.27 [0.03, 2.23] | -50 -25 0 25 50 Favours [3D group] Favours [Non-3D group] Risk Ratio M-H, Fixed, 95% Cl |
| She 2018 Total (95% CI) Heterogeneity: Tau ² = 3 Test for overall effect: 2 Study or Subgroup Chen 2020 Liu 2019 Liu 2019* | 141.9 370.60; (Z = 2.04 3E 0 Eve | 29.1 Chi ² = 1! (P = 0.0) group ents T 0 1 0 | 51 552 51.73, 0 (4) 0 0 1 51 39 32 | 160.9 df = 9 (P Non-3D Events 8 5 5 | 31.5 < 0.000 group Tot | 626 001); I ² 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 | 10.0% 100.0% = 94% 2001 M 3.6% 3.4% 3.0% | -19.00 [-0.07, -7.23] -13.03 [-25.56, -0.50] -13.03 | -50 -25 0 25 50 Favours [3D group] Favours [Non-3D group] Risk Ratio M-H. Fixed, 95% Cl |
| She 2018 Total (95% CI) Heterogeneity: Tau ² = 3 Test for overall effect: 2 Study or Subgroup Chen 2020 Liu 2019 Liu 2019* Total (95% CI) | 141.9 370.60; C Z = 2.04 3E • Eve | 29.1 $Chi^{2} = 1!$ (P = 0.0) group ents T 0 1 0 | 51 552 51.73, 0 (4) 0 0 1 51 39 32 32 122 | 160.9 df = 9 (P Non-3D Events 8 5 5 | 31.5 < 0.000 group Tot | 626 626 001); I ² al We 38 5: 33 2: 33 2: 34 2: 35 2: 35 2: 35 2: 3 | 10.0% 100.0% = 94% 2007 2007 2007 2007 2007 2007 2007 200 | -19.00 [-0.07, -7.23] -19.00 [-30.77, -7.23] -13.03 [-25.56, -0.50] | -50 -25 0 25 50 Favours [3D group] Favours [Non-3D group] Risk Ratio M-H, Fixed, 95% Cl |
| She 2018 Total (95% CI) Heterogeneity: Tau ² = 3 Test for overall effect: 2 Study or Subgroup Chen 2020 Liu 2019 Liu 2019* Total (95% CI) Total events | 141.9 370.60; C Z = 2.04 3E b Eve | 29.1 $Chi^{2} = 1!$ (P = 0.0) group ents T 0 1 0 1 | 51 552 51.73, 0 44) 0 0 51 39 32 32 122 | 160.9 160.9 df = 9 (P Non-3D Events 8 5 5 5 | 31.5 < 0.000 group Tot | 51 626 001); I ² al We 38 5 53 2 53 2 53 2 | 10.0% 100.0% = 94% 2007 2007 2007 2007 2007 2007 2007 200 | -19.00 [-0.07, -7.23] -19.00 [-30.77, -7.23] -13.03 [-25.56, -0.50] | -50 -25 0 25 50 Favours [3D group] Favours [Non-3D group] Risk Ratio M-H. Fixed, 95% Cl |
| She 2018 Total (95% CI) Heterogeneity: Tau ² = 3 Test for overall effect: 2 Study or Subgroup Chen 2020 Liu 2019 Liu 2019* Total (95% CI) Total events Heterogeneity: Chi ² | 141.9 370.60; C Z = 2.04 3E Eve | 29.1 $Chi^{2} = 19$ (P = 0.0) 9 group 9 group 1 0 1 0 1 0 1 0 1 0 1 0 | 51 552 51.73, 0 4) 51 51 39 32 122 P = 0 | 160.9 160.9 df = 9 (P Non-3D Events 8 5 5 5 18 5 8 18 5 8 18 | 31.5 < 0.000 group Tot | 51 626 001); I ² 38 5: 53 2: 53 2: 53 2: 53 2: | 10.0% 100.0% = 94% eight <u>N</u> 3.6% 3.4% 3.0% 0.0% | -19.00 [-0.07, -7.23] -19.00 [-30.77, -7.23] -13.03 [-25.56, -0.50] | -50 -25 0 25 50 Favours [3D group] Favours [Non-3D group] Risk Ratio M-H, Fixed, 95% Cl |
| She 2018 Total (95% Cl) Heterogeneity: Tau ² = 3 Test for overall effect: 2 Study or Subgroup Chen 2020 Liu 2019 Liu 2019* Total (95% Cl) Total events Heterogeneity: Chi ² Test for overall effect | 141.9 370.60; C Z = 2.04 3E E Eve = 1.08, ' tt: Z = 2. | 29.1 Chi ² = 1! (P = 0.0) group ents T 0 1 0 1 0 1 0 4f = 2 (.99 (P = | 51 552 51.73, 0 44) 51 39 32 122 P = 0. = 0.003 | 160.9 160.9 df = 9 (P Non-3D Events 8 5 5 5 18 58); l ² = 3) | 31.5 < 0.000 group Tot 5 5 14 | 51 626 001); I ² <u>al We</u> 38 5 53 2 53 2 53 2 53 2 | 10.0% 100.0% = 94% aight <u>N</u> 3.6% 3.4% 3.0% | -19.00 [-01.07, -21.35] -19.00 [-30.77, -7.23] -13.03 [-25.56, -0.50] | -50 -25 0 25 50 Favours [3D group] Favours [Non-3D group] Risk Ratio M-H, Fixed, 95% Cl 2 0.1 1 10 500 Favours [3D group] Favours [Non-3D group] |
| She 2018 Total (95% CI) Heterogeneity: Tau ² = 3 Test for overall effect: 2 Study or Subgroup Chen 2020 Liu 2019 Liu 2019 Liu 2019* Total (95% CI) Total events Heterogeneity: Chi ² Test for overall effect | 141.9 370.60; C Z = 2.04 3E E Eve = 1.08, c t: Z = 2. 3E | 29.1 Chi ² = 1! (P = 0.0) group ents T 0 1 0 1 df = 2 (.99 (P = | 51 552 51.73, 0 4) 51 39 32 122 P = 0. = 0.003 | 160.9 160.9 tif = 9 (P Non-3D Events 8 5 5 5 18 58); l ² = 3) Non-3 | 31.5 < 0.000 group Tot 3 5 5 14 0% | 51 626 001); I ² 0 al Wa 38 5 53 2 53 2 53 2 53 2 53 2 53 2 | 10.0% 100.0% = 94% 2010 100 100 100 100 100 100 100 100 100 | -19.00 [-30.77, -7.23] -19.00 [-30.77, -7.23] -13.03 [-25.56, -0.50] - Risk Ratio <u>A-H. Fixed. 95% Cl</u> 0.04 [0.00, 0.74] 0.27 [0.03, 2.23] 0.15 [0.01, 2.60] 0.12 [0.03, 0.48] - - Mean Difference | -50 -25 0 25 50 Favours [3D group] Favours [Non-3D group] Risk Ratio M-H, Fixed, 95% Cl 2 0.1 1 10 500 Favours [3D group] Favours [Non-3D group] Mean Difference |
| She 2018 Total (95% CI) Heterogeneity: Tau ² = : Test for overall effect: 2 Study or Subgroup Chen 2020 Liu 2019 Liu 2019* Total (95% CI) Total events Heterogeneity: Chi ² Test for overall effect | 141.9 370.60; C Z = 2.04 3E E Eve = 1.08, v ct: Z = 2. 3E Mean | 29.1 $Chi^2 = 19$ (P = 0.0) 9 group ants T 0 1 0 1 0 1 0 1 0 1 0 9 9 (P = 0.0) 9 group 1 0 9 (P = 0.0) 9 group 1 0 9 group 1 1 0 1 1 1 1 1 1 1 1 | 51 552 51.73, 0 51 51 39 32 122 P = 0. = 0.003 5 | 160.9 160.9 160.9 160.9 Non-3D Events 5 5 5 18 5 8 5 8); l ² = 3) Non-3 Mean | 31.5 < 0.000 group Tot 3 5 14 0% 8D grou SD 7 | 626 51 626 0001); I ² 0 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 | 10.0% 100.0% = 94% 24 24 24 24 25 24 25 25 25 25 25 25 25 25 25 25 | -19.00 [-30.77, -7.23] -19.00 [-30.77, -7.23] -13.03 [-25.56, -0.50] | -50 -25 0 25 50 Favours [3D group] Favours [Non-3D group] Risk Ratio M-H, Fixed, 95% Cl 2 0.1 1 10 500 Favours [3D group] Favours [Non-3D group] Mean Difference IV. Random. 95% Cl |
| She 2018 Total (95% CI) Heterogeneity: Tau ² = : Test for overall effect: 2 Study or Subgroup Chen 2020 Liu 2019 Liu 2019* Total (95% CI) Total events Heterogeneity: Chi ² Test for overall effect Study or Subgroup Wu 2021 | 141.9 370.60; C Z = 2.04 3E E Eve = 1.08, ' tt: Z = 2. 3E Mean | 29.1 Chi ² = 19 (P = 0.0) group ents T 0 1 0 1 0 1 0 1 0 1 0 9 (P = 0.0) group ents T 0 1 0 0 9 (P = 0.0) group ents T 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 | 51 552 51.73, (-4) 51 39 32 122 P = 0. = 0.003 0 0 Total | 160.9 160.9 df = 9 (P Non-3D Events 5 5 18 58); l ² = 18 58); l ² = 3) Non-3 Mean | 31.5 31.5 31.5 31.5 31.5 31.5 31.5 31.5 | 51 626 001); I ² 0 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 | 10.0% 100.0% = 94% aight M 3.6% 3.4% 3.0% 0.0% Weight 48.4% | -19.00 [-30.77, -7.23] -19.00 [-30.77, -7.23] -13.03 [-25.56, -0.50] | -50 -25 0 25 50 Favours [3D group] Favours [Non-3D group] Risk Ratio M-H, Fixed, 95% Cl 2 0.1 1 10 500 Favours [3D group] Favours [Non-3D group] Mean Difference IV. Random, 95% Cl |
| She 2018 Total (95% CI) Heterogeneity: Tau ² = 3 Test for overall effect: 2 Study or Subgroup Chen 2020 Liu 2019 Liu 2019* Total (95% CI) Total events Heterogeneity: Chi ² Test for overall effect Study or Subgroup Wu 2021 She 2018 | 141.9 370.60; C Z = 2.04 3E E Eve = 1.08, f tt: Z = 2. 3E Mean 9.2 | 29.1 29.1 $(P = 0.0)$ $9 group$ 1 0 1 0 1 0 1 0 1 0 $9 (P = 0.0)$ $2 (P = 0.0)$ 2 | 51 552 51.73, (4) 51 30 32 32 122 P = 0.003 55 55 55 55 | 160.9 160.9 160.9 160.9 Non-3D 18 58); I ² = 18 58); I ² = 18 58); I ² = 18 58); I ² = 18 58); I ² = 3) | 31.5 31.5 solution so | 51 626 001); ² 6 7 8 8 53 2 33 2 33 2 4 10 55 55 5 | 10.0% 100.0% = 94% aight M 3.6% 3.4% 3.0% 0.0% Weight 48.4% 51.6% | -19.00 [-00.77, -7.23] -19.00 [-30.77, -7.23] -13.03 [-25.56, -0.50] | -50 -25 0 25 50 Favours [3D group] Favours [Non-3D group] Risk Ratio M-H, Fixed, 95% Cl 2 0.1 1 10 500 Favours [3D group] Favours [Non-3D group] Mean Difference IV. Random, 95% Cl |
| She 2018 Total (95% CI) Heterogeneity: Tau ² = 3 Test for overall effect: 2 Study or Subgroup Chen 2020 Liu 2019 Liu 2019* Total (95% CI) Total events Heterogeneity: Chi ² Test for overall effect Study or Subgroup Wu 2021 She 2018 | 141.9 370.60; C Z = 2.04 3E Eve = 1.08, - st: Z = 2. 3E Mean 9.2 5 | 29.1 29.1 $(P = 0.0)$ $9 group$ 1 0 1 0 1 $df = 2 ($ $.99 (P = 0.0)$ $9 group$ $2 2.3$ $5 1.1$ | 51 552 51.73, (4) 51 39 32 51 32 32 122 P = 0.000 55 51 | 160.9 160.9 160.9 160.9 Non-3D 18 58); I ² = 18 58); I ² = 18 58); I ² = 18 58); I ² = 3) Non-3 Mean 9.4 3 | 31.5 31.5 group Tot 5 5 5 14 0% BD grou 2.3 0.8 | 51 626 001); ² 6 6 7 8 8 5 3 2 3 2 4 10 5 5 5 5 1 | 10.0% 100.0% = 94% aight M 3.6% 3.4% 3.0% 0.0% Weight 48.4% 51.6% | -19.00 [-30.77, -7.23] -19.00 [-30.77, -7.23] -13.03 [-25.56, -0.50] | -50 -25 0 25 50 Favours [3D group] Favours [Non-3D group] Risk Ratio M-H, Fixed, 95% Cl 2 0.1 1 10 500 Favours [3D group] Favours [Non-3D group] Mean Difference IV. Random, 95% Cl |
| She 2018 Total (95% CI) Heterogeneity: Tau ² = : Test for overall effect: 2 Study or Subgroup Chen 2020 Liu 2019 Liu 2019* Total (95% CI) Total events Heterogeneity: Chi ² Test for overall effect Study or Subgroup Wu 2021 She 2018 Total (95% CI) | 141.9 370.60; C Z = 2.04 3E Eve = 1.08, ' t: Z = 2. 3E <u>Mean</u> 9.2 5 | 29.1 29.1 $(P = 0.0)$ $9 group$ 1 0 1 0 1 $df = 2 ($ $.99 (P = 0.0)$ $9 group$ 2.3 1.1 | 51 552 51.73, (4) 51 39 32 122 P = 0.003 51 55 51 55 51 55 51 55 51 51 55 51 51 55 51 51 55 51 51 55 51 51 55 51 51 55 51 51 55 51 51 55 51 51 55 51 51 55 51 51 55 51 51 55 51 51 55 51 51 55 51 55 51 51 55 51 55 51 55 51 55 51 55 51 55 51 55 51 55 51 55 51 55 51 55 51 55 51 55 51 55 51 55 51 55 51 55 51 55 51 55 51 106 55 51 106 55 51 106 55 51 106 55 51 106 55 51 106 55 51 106 55 51 106 | 160.9 160.9 160.9 160.9 Non-3D 18 5 5 18 5 5 18 5 5 18 5 5 18 5 18 5 3) Non-3 Mean 9.4 3 | 31.5 31.5 group Tot 5 5 5 14 0% SD grou 2.3 0.8 | 51 626 001); ² 6 6 7 8 8 5 7 3 3 2 3 3 2 3 3 2 3 3 2 3 3 2 4 10 5 5 5 5 1 106 | 10.0% 100.0% = 94% aight M 3.6% 3.4% 3.0% 0.0% Weight 48.4% 51.6% 100.0% | -19.00 [-30.77, -7.23] -19.00 [-30.77, -7.23] -13.03 [-25.56, -0.50] | -50 -25 0 25 50 Favours [3D group] Favours [Non-3D group] Risk Ratio M-H, Fixed, 95% Cl 2 0.1 1 10 500 Favours [3D group] Favours [Non-3D group] Mean Difference IV. Random, 95% Cl |
| She 2018 Total (95% Cl) Heterogeneity: Tau ² = 3 Test for overall effect: 2 Study or Subgroup Chen 2020 Liu 2019 Liu 2019* Total (95% Cl) Total events Heterogeneity: Chi ² Test for overall effect Study or Subgroup Wu 2021 She 2018 Total (95% Cl) Heterogeneity: Tau ² = | 141.9 370.60; C Z = 2.04 3E Eve = 1.08, - | 29.1 29.1 $(P = 0.0)$ 9 group 1 0 1 0 1 $df = 2 ($ $.99 (P = 0.0)$ 2.3 $5 1.1$ $Chi^{2} = 2^{-1}$ | 51 552 51.73, (4) 51 39 32 122 P = 0.003 51 51 32 122 P = 0.003 55 51 55 51 55 51 106 1.17, (d) | 160.9 160.9 160.9 160.9 160.9 8 5 5 5 18 58 ; $1^2 =$ 18 58 ; $1^2 =$ 18 58 ; $1^2 =$ 18 5 18 58 ; $1^2 =$ 18 5 18 5 5 18 5 18 5 18 5 18 5 18 5 18 5 18 5 3 12 | 31.5 31.5 group Tot 5 5 5 7 14 0% BD grou 5 2.3 0.8 | 51 626 001); ² al Wr 53 33 2 33 2 4 10 55 51 55 51 106 01); ² | 10.0% 100.0% = 94% aight M 3.6% 3.4% 3.0% 0.0% Weight 48.4% 51.6% 100.0% = 95% | -19.00 [-30.77, -7.23] -19.00 [-30.77, -7.23] -13.03 [-25.56, -0.50] | 2 0.1 1 10 500 Favours [3D group] Favours [Non-3D group] Risk Ratio M-H, Fixed, 95% Cl 2 0.1 1 10 500 Favours [3D group] Favours [Non-3D group] Mean Difference IV. Random, 95% Cl |
| She 2018 Total (95% Cl) Heterogeneity: Tau ² = 3 Test for overall effect: 2 Study or Subgroup Chen 2020 Liu 2019 Liu 2019 Total (95% Cl) Total events Heterogeneity: Chi ² Test for overall effect Wu 2021 She 2018 Total (95% Cl) Heterogeneity: Tau ² = Test for overall effect: | 141.9 370.60; C Z = 2.04 3C Eve = 1.08, 1 t: Z = 2. 3C Mean 9.2 5 = 2.31; C : Z = 0.8 | 29.1 29.1 (P = 0.0) group ents T 0 1 0 1 0 1 0 1 0 1 0 1 0 9 9 (P = 0.0) group ents T 0 1 0 1 0 5 group ents T 0 1 0 5 group ents T 0 1 0 5 group ents T 0 1 0 group ents T 0 1 0 group ents T 0 1 0 group ents T 0 1 0 group ents T 0 1 0 group ents T 0 f group ents T 0 f f f f f f f f | 51 552 51.73, (4) 6 10 51 39 32 122 P = 0.0 55 51 106 1.17, d 0.39) | 160.9 160.9 df = 9 (P Non-3D Events 8 5 5 18 58); I ² = 3) Non-3 Mean 9.4 3 f = 1 (P - | 31.5 31.5 (0.000 <u>group</u> <u>Tot</u> 5 5 5 5 14 0% 8D grou <u>SD</u> 2.3 0.8 (0.000 | 51 626 6001); ² al Wr 53 22 33 22 4 10 55 51 106 01); ² | 10.0% 100.0% = 94% 2ight M 3.6% 3.4% 3.0% 0.0% Weight 48.4% 51.6% 100.0% = 95% | -19.00 [-30.77, -7.23] -19.00 [-30.77, -7.23] -13.03 [-25.56, -0.50] | -50 -25 0 25 50 Favours [3D group] Favours [Non-3D group] Risk Ratio M-H, Fixed, 95% Cl 2 0.1 1 10 500 Favours [3D group] Favours [Non-3D group] Mean Difference IV. Random, 95% Cl -4 -2 0 2 4 Favours [2D group] 5 |

the non-3D group. Arrhythmia, pulmonary air leakage, atrial fibrillation, pulmonary infection and pneumonia were top 5 postoperative complications in the 3D group. The number of resected lymph nodes (LNs), postoperative drainage time, postoperative forced expiratory volume in the first second (post-op FEV1) and postoperative drainage volume were similar in the two groups.

For intraoperative outcomes, the patients in the 3D group showed an obvious improvement in blood loss, operative

time, and conversion rate (conversion from segmentectomy to thoracotomy or lobectomy) compared with patients in the non-3D group. With the latest developments in 3D lung simulation imaging, the quality of imaging in a 3D system is similar to that in stereo vision. Because the 3D structure of the lung was examined adequately before surgery, the risk of bleeding during surgery was reduced. The surgeon obtained a better understanding of the anatomy of the nodule by watching the preoperative 3D lung simulation, which may have led to the



FIGURE 3 | Forest plots of hospitalization indicators: postoperative hospital stay (A), complications (B), postoperative drainage time (C), postoperative drainage volume (D), and postoperative Forced Expiratory Volume in the first second (E).

| Postoperative complications | Studies involved | 3D gro | up | Non-3D g | Iroup | Total incidence | Differences (95% CI) | l ² (%) | Ρ |
|-----------------------------|------------------|-------------|-------|-------------|-------|-----------------|----------------------|--------------------|-------|
| | | Event/total | % | Event/total | % | | | | |
| Pulmonary air leakage | 8 | 15/552 | 2.72% | 24/437 | 5.49% | 3.94% | 0.53 [0.28–1.01] | 0 | 0.05 |
| Pneumonia | 6 | 7/405 | 1.73% | 8/362 | 2.21% | 1.96% | 0.83 [0.33–2.08] | 0 | 0.69 |
| Atelectasis | 5 | 6/371 | 1.62% | 7/310 | 2.26% | 1.91% | 0.72 [0.26–2.01] | 0 | 0.53 |
| Hemoptysis | 4 | 3/207 | 1.45% | 16/194 | 8.25% | 4.74% | 0.19 [0.06–0.58] | 0 | 0.004 |
| Arrhythmia | 3 | 7/132 | 5.30% | 11/124 | 8.87% | 7.03% | 0.67 [0.28–1.60] | 0 | 0.37 |
| Atrial fibrillation | 2 | 2/91 | 2.20% | 0/87 | 0.00% | 11.23% | 2.83 [0.30–26.68] | 0 | 0.36 |
| Cerebral infarction | 2 | 2/147 | 1.36% | 1/75 | 1.33% | 1.35% | 0.91 [0.12–7.17] | 0 | 0.93 |
| Pulmonary infection | 2 | 3/147 | 2.04% | 2/75 | 2.67% | 2.25% | 0.75 [0.13–4.10] | 0 | 0.74 |
| Liquid pneumothorax | 1 | 1/96 | 1.04% | 0/37 | 0.00% | 0.75% | 1.18 [0.05–28.22] | - | 0.92 |
| Postoperative hemothorax | 1 | 1/96 | 1.04% | 0/37 | 0.00% | 0.75% | 1.18 [0.05–28.22] | - | 0.92 |
| Pleural effusion | 1 | 1/96 | 1.04% | 0/37 | 0.00% | 0.75% | 1.18 [0.05–28.22] | - | 0.92 |

TABLE 3 | Postoperative complications.

Cl, Confidence interval; COPD, Chronic obstructive pulmonary disease.

shorter operation time. Similarly, with preoperative 3D lung simulation scanning, conversion to lobectomy was less likely. However, there were no differences in the number resected LNs between these two groups. Jiao et al. found that their 3D group had results that were similar to those of their traditional 2D procedure group (26). Regarding the number of resected lymph nodes, preoperative 3D lung simulation provided a better understanding of the position of LNs than traditional 2D procedures, thus increasing the number of resected LNs.

For postoperative outcomes, the postoperative hospital stay and total number of complications in the 3D group were better than those of the non-3D group (27). However, Hu W et al. found that the postoperative hospital stay and total number of complications such as pneumonia, hemoptysis, arrhythmia, and pulmonary air leakage were not significantly different between the two groups (9). Postoperative complications are often caused by multiple factors, usually intraoperative conditions, postoperative patient care and primary underlying disease. A study with a larger sample is needed to further confirm and clarify these findings. For the postoperative drainage time, postoperative FEV1 and postoperative drainage volume, we found little difference between the two groups. However, Xu et al. reported that their 3D group had notably different postoperative drainage times compared with their 2D group (28). On the one hand, the difference between the two studies might caused by differences in the condition of the patients, for example, the basic physical condition of the patients and the patients' other underlying diseases, as well as differences in clinical nursing practices (29). It is worth mentioning that the proficiency of the surgeons who performed segmentectomy for lung cancer also may be partly responsible for the difference between the two studies. On the other hand, preoperative 3D lung simulation improved preoperative preparation, which therefore may have reduced the risks of difficulties and accidents during the operation (30), resulting in the 3D group having better postoperative drainage times.

There are still many shortcomings in our research. First, the sample size was too small to allow credible conclusions to be drawn, and the number of patients was generally <100 in the 3D group (31). Second, only one study was a randomized controlled trial, and the remaining studies were cohort studies of lower quality than the RCT. In the future, more randomized controlled trials and studies with larger sample sizes are needed. Third, none of these 8 studies reported survival data, which is an important clinical result. However, this situation is likely due to the development of preoperative 3D lung simulation in recent years, which limits the availability of longer-term survival data at present and demands the accumulation of time and efforts. Fourth, all studies and patients were from China, which may lead to racial bias in the results, which may not be applicable to other regions and populations. Last, the indicators monitored were not consistent among the studies. Some studies focused on intraoperative indicators, but other studies tended to analyze postoperative indicators. A broad and unified standard is necessary to standardize and evaluate the two surgical methods.

Overall, preoperative 3D lung simulation showed a beneficial improvement in perioperative outcomes and postoperative outcomes compared with non-3D procedures for segmentectomy with lung cancer. The top 5 common complications in the 3D group were arrhythmia, pulmonary air leakage, atrial fibrillation, pulmonary infection and pneumonia. Because of the above limitations, our results should be verified in largesample randomized controlled trials. Preoperative 3D lung simulation improves surgical accuracy and safety and is worthy of clinical promotion.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/**Supplementary Material**, further inquiries can be directed to the corresponding author/s.

AUTHOR CONTRIBUTIONS

ZX and WZ had full access to all of the data in the manuscript and takes responsibility for the integrity of the data and the accuracy of the data analysis. ZX, JX, and WZ: drafting of the manuscript. ZX, BW, XZ, NF, YW, and WZ: critical revision of the manuscript for important intellectual content. ZX, BW, XZ, and YW: statistical analysis. ZX and WZ: supervision. All authors: concept, design, acquisition, analysis, or interpretation of data. All authors contributed to the article and approved the submitted version.

FUNDING

This study was supported by Natural Science Foundation of Jiangxi Province (Grant number: 20212BAB206050), Science and technology planning project of Health Commission of Jiangxi Province (Grant number: 202110045) and Science and technology planning project of Jiangxi Administration of traditional Chinese Medicine (Grant number: 2020B0108). The funding had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data;

REFERENCES

- Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. (2021) 71:7–33. doi: 10.3322/caac.21654
- National Lung Screening Trial Research Team, Church TR, Black WC, Aberle DR, Berg CD, Clingan KL, et al. Results of initial low-dose computed tomographic screening for lung cancer. N Engl J Med. (2013) 368:1980– 91. doi: 10.1056/NEJMoa1209120
- Cao J, Yuan P, Wang Y, Xu J, Yuan X, Wang Z, et al. Survival rates after lobectomy, segmentectomy, and wedge resection for non-small cell lung cancer. *Ann Thorac Surg.* (2018) 105:1483– 91. doi: 10.1016/j.athoracsur.2018.01.032
- Ma Q, Bao T, Zhang H, Liang C, Liu D. Anatomical video-assisted thoracoscopic surgery segmentectomies based on the three-dimensional reformation images. J Vis Surg. (2017) 3:21. doi: 10.21037/jovs.2017.02.01
- Postmus PE, Kerr KM, Oudkerk M, Senan S, Waller DA, Vansteenkiste J, et al. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol.* (2017) 28:iv1–21. doi: 10.1093/annonc/mdx222
- Liu X, Zhao Y, Xuan Y, Lan X, Zhao J, Lan X, et al. Three-dimensional printing in the preoperative planning of thoracoscopic pulmonary segmentectomy. *Transl Lung Cancer Res.* (2019) 8:929–37. doi: 10.21037/tlcr.2019.11.27
- Chen Y, Zhang J, Chen Q, Li T, Chen K, Yu Q, et al. Three-dimensional printing technology for localised thoracoscopic segmental resection for lung cancer: a quasi-randomised clinical trial. *World J Surg Oncol.* (2020) 18:223. doi: 10.1186/s12957-020-01998-2
- Xu G, Chen C, Zheng W, Zhu Y, Chen H, Cai B. Application of the IQQA-3D imaging interpretation and analysis system in uniportal video-assisted thoracoscopic anatomical segmentectomy: a series study. *J Thorac Dis.* (2019) 11:2058–66. doi: 10.21037/jtd.2019.04.83
- Hu W, Zhang K, Han X, Zhao J, Wang G, Yuan S, et al. Three-dimensional computed tomography angiography and bronchography combined with three-dimensional printing for thoracoscopic pulmonary segmentectomy in stage IA non-small cell lung cancer. *J Thorac Dis.* (2021) 13:1187– 95. doi: 10.21037/jtd-21-16
- 10. Xue L, Fan H, Shi W, Ge D, Zhang Y, Wang Q, et al. Preoperative 3dimensional computed tomography lung simulation before video-assisted

preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

ACKNOWLEDGMENTS

The authors thank Professor Jichun Liu, MD (Department of Thoracic Surgery, The Second Affiliated Hospital of Nanchang University) for his statistical advice.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fsurg. 2022.856293/full#supplementary-material

Supplementary Figure 1 | Sensitivity analysis of blood loss (A), operative time (B), and postoperative hospital day (C).

Supplementary Figure 2 | Publication bias of postoperative drainage time (A), operative time (B), and postoperative hospital day (C).

Supplementary Table 1 | PRISMA 2009 Checklist.

Supplementary Table 2 | The strategy of searching.

Supplementary Table 3 | GRADE quality assessment of the results through treatment strategy and research design.

thoracoscopic anatomic segmentectomy for ground glass opacity in lung. J Thorac Dis. (2018) 10:6598–605. doi: 10.21037/jtd.2018.10.126

- 11. She XW, Gu YB, Xu C, Li C, Ding C, Chen J, et al. Three-dimensional (3D)computed tomography bronchography and angiography combined with 3D-video-assisted thoracic surgery (VATS) versus conventional 2D-VATS anatomic pulmonary segmentectomy for the treatment of non-small cell lung cancer. *Thorac Cancer.* (2018) 9:305–9. doi: 10.1111/1759-7714.12585
- Qiu B, Ji Y, He H, Zhao J, Xue Q, Gao S. Three-dimensional reconstruction/personalized three-dimensional printed model for thoracoscopic anatomical partial-lobectomy in stage I lung cancer: a retrospective study. *Transl Lung Cancer Res.* (2020) 9:1235–46. doi: 10.21037/tlcr-20-571
- Wu X, Li T, Zhang C, Wu G, Xiong R, Xu M, et al. Comparison of perioperative outcomes between precise and routine segmentectomy for patients with early-stage lung cancer presenting as ground-glass opacities: a propensity score-matched study. *Front Oncol.* (2021) 11:661821. doi: 10.3389/fonc.2021.661821
- Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *BMJ*. (2009) 339:b2535. doi: 10.1136/bmj.b2535
- Wells GA, Shea BJ, O'Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of non-randomised studies in meta-analyses (2012). Available online at: http://www.ohri. ca/programs/clinical_epidemiology/oxford. htm
- Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? *Control Clin Trials.* (1996) 17:1–12. doi: 10.1016/0197-2456(95)00134-4
- Guyatt GH, Oxman AD, Schünemann HJ, Tugwell P, Knottnerus A. GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology. J Clin Epidemiol. (2011) 64:380–2. doi: 10.1016/j.jclinepi.2010. 09.011
- Langhorne P. Bias in meta-analysis detected by a simple, graphical test. Prospectively identified trials could be used for comparison with metaanalyses. *BMJ*. (1998) 316:471.
- Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. *Biometrics*. (1994) 50:1088–101. doi: 10.2307/2533446

- Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN (2008). *Int J Cancer*. (2010) 127:2893–917. doi: 10.1002/ijc.25516
- World Health Organization. *Geneva: Cancer.* (2018). Available online at: https://www.who.int/news-room/fact-sheets/detail/ cancer (accessed April 24, 2020).
- Bernicker EH, Xiao Y, Abraham A, Yang B, Croix DA, Redpath S, et al. Adherence to national comprehensive cancer network ALK testing guidelines for patients with advanced non-small cell lung cancer in U.S. community medical centers. *Oncologist.* (2021) 26:e1050–7. doi: 10.1002/onco.13779
- 23. Zou L, Guo T, Ye L, Zhou Y, Chu L, Chu X, et al. Outcomes for surgery in stage IA large cell lung neuroendocrine compared with other types of non-small cell lung cancer: a propensity score matching study based on the Surveillance, Epidemiology, and End Results (SEER) database. *Front Oncol.* (2020) 10:572462. doi: 10.3389/fonc.2020.5 72462
- Nakamura K, Saji H, Nakajima R, Okada M, Asamura H, Shibata T et al. A phase III randomized trial of lobectomy versus limited resection for smallsized peripheral non-small cell lung cancer (JCOG0802/ WJOG4607L). *Jpn J Clin Oncol.* (2010) 40:271–4. doi: 10.1093/jjco/hyp156
- Chan AC, Chung SC, Yim AP, Lau JY, Ng EK, Li AK. Comparison of two dimensional vs three-dimensional camera systems in laparoscopic surgery. Surg Endosc. (1997) 11:438–0. doi: 10.1007/s0046499 00385
- Jiao P, Wu QJ, Sun YG, Ma C, Tian WX, Yu HB, et al. Comparative study of three-dimensional versus two-dimensional video-assisted thoracoscopic two-port lobectomy. *Thorac Cancer*. (2017) 8:3–7. doi: 10.1111/1759-7714. 12387
- Maki R, Miyajima M, Ogura K, Tada M, Takahashi Y, Arai W, et al. Pulmonary vessels and bronchial anatomy of the left lower lobe. *Surg Today.* (2020) 50:1081–90. doi: 10.1007/s00595-020-01991-y

- Xu Y, Chen N, Ma A, Wang Z, Zhang Y, Liu C, et al. Threedimensional versus two-dimensional video-assisted thoracic surgery for thoracic disease: a meta-analysis. *Interact Cardiovasc Thorac Surg.* (2017) 25:862–71. doi: 10.1093/icvts/ivx219
- Cavalheri V, Granger C. Preoperative exercise training for patients with non-small cell lung cancer. *Cochrane Database Syst Rev.* (2017) 6:CD012020. doi: 10.1002/14651858.CD012020.pub2
- Liu G, Hu H, Dong P, Zhang S, Mao Z. Modified left subsuperior segmentectomy via 2-cm uniportal video-assisted thoracoscopic surgery. Surg Today. (2021) 51:172–5. doi: 10.1007/s00595-020-02009-3
- Rodríguez Del Águila M, González-Ramírez A. Sample size calculation. Allergol Immunopathol. (2014) 42:485–92. doi: 10.1016/j.aller.2013.03.008

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Xiang, Wu, Zhang, Feng, Wei, Xu and Zhang. This is an openaccess article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.